Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center's decade of experience.

Front Oncol · 2024 · PMC10915752 · PMID 38450188

Europe PMC DOI

hedged sentences

0.0540

closest p · 1.1× alpha

0.2300

boldest claim

The sentences

showed a trendp=0.054so close (0.05 < p ≤ 0.1)

PFS showed a trend in favor of Arm A (log-rank p=0.054).

also in 53,322 other papers

did not reach statistical significancep=0.23not close (p > 0.1)

There was a trend toward improved PFS in BRAFwt patients compared with BRAFm, however, it did not reach statistical significance (p=0.23) ( Figure 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.